Tuesday, 3 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Investor Presentation

Vijaya Diagnostic Centre Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹2,554 Mn (+26.7%), EBITDA ₹1,128 Mn (44.1% margin), PAT ₹595 Mn (23.3%). Strategy: hub-and-spoke densification, Bengaluru/Hyderabad hubs, Guwahati entry.

Highlights
Revenue growthQ2 +26.7% YoY; existing centres ~20%.
MarginsEBITDA margin 44.1%, +355 bps YoY; PAT margin 23.3%.
Demand visibilityWellness testing growth 27.1% Q2; Tier-2/3 scaling.
Management confidenceCEO: 'sustained strong growth momentum'.

Growth

Q2 revenue +26.7% YoY, EBITDA +37.8%, PAT +37.4%. H1 FY27 revenue +24.8%, PAT +37.5%.

Outlook

No numeric growth guidance. 3 hubs+7 spokes H2 FY27; 3 hubs Q1 FY28. Arya Wellness Guwahati ₹46.2 Cr, 8-9x EBITDA.

Risks

Finance costs +45.4% YoY; other expenses +20.4%; no explicit risks flagged beyond standard safe-harbour.

Last quarter's promises, checked

Delivered

  • Guided EBITDA margin above 40% (40-45% range) → delivered 44.1% (= BEAT)
  • Guided high double-digit FY27 growth → H1 FY27 revenue +24.8% (= BEAT)

Partly delivered

  • Guided 9 hubs + 10-12 spokes in 12 months → now 3 hubs + 7 spokes in H2 FY27 and 3 hubs in Q1 FY28 (= PARTIAL)
Source

Investor Presentation filed with BSE, NSE: VIJAYA. Summary written with AI assistance from the document.

Read the document ↗

Vijaya Diagnostic Centre Ltd: key numbers

Share price
₹1,447.10
Market cap
₹14,905 Cr
Revenue (annual)
₹814.2 Cr
Net profit (annual)
₹173.0 Cr
P/E (TTM)
79.5×Sector 53.8×
Promoter holding
52.46%-0.05% QoQ
FII holding
10.67%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Vijaya Diagnostic Centre Ltd

All →